Pharmaceutical Technology

MAY 30, 2023

Medsenic reached licensing, marketing and supply agreements with Phebra for OATO in May 2021. Biotechnology company BioSenic’s affiliate Medsenic has amended its licence agreement with Australia-based pharmaceutical company Phebra for the oral formulation of arsenic trioxide (OATO).

Clinical Supply 130

Clinical Supply FDA Approval Licensing Licensing 130

Pharmaceutical Technology

MAY 30, 2023

The company’s last deal included an exclusive license agreement with the Cardiff, UK-headquartered specialty pharmaceuticals company Diurnal group for the commercialisation of Efmody (hydrocortisone) in Switzerland. Separate from drug development, the Italian company also offers contract manufacturing and clinical supply services.

Contract Manufacturing 130

Contract Manufacturing Clinical Supply Drugs Licensing 130

The Pharma Data

AUGUST 4, 2020

. UK-based Oxford Biomedica has signed a new development, manufacture and license agreement with Beam Therapeutics for next-generation CAR-T therapeutics. The agreement grants Beam a non-exclusive license to Oxford Biomedica’s LentiVector platform, for tis application in next-generation CAR-T programmes in oncology.

Gene Editing 52

Gene Editing Licensing Licensing Clinical Supply 52

XTalks

JUNE 27, 2023

“They have a bag that is focused on tech, and they have a bag that’s focused on the clinical supplies that they need in order to treat a wide range of conditions. They bring over a hundred different supplies into the home.”

Doctor 98

Doctor Doctors Licensing Licensing 98

pharmaphorum

NOVEMBER 2, 2022

CSL’s vaccines unit CSL Seqirus division is paying Arcturus $200 million upfront to gain access to its self-amplifying mRNA technology platform and exclusive licenses to several vaccine candidates, with another $4.3 billion on offer in milestones if the programmes meet development and commercial objectives.

Vaccination 52

Vaccination Vaccine Immune Response Gene Therapy 52

The Pharma Data

JANUARY 10, 2021

Among the factors that may result in differences are MorphoSys’ expectations regarding risks and uncertainties related to the impact of the COVID-19 pandemic to MorphoSys’ business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical (..)

Containment 52

Containment Clinical Development Antibody Development 52

The Pharma Data

AUGUST 15, 2021

VTX-801 is a novel investigational gene therapy to be evaluated in a Phase 1/2 clinical trial to determine the safety, tolerability, and pharmacological activity of a single intravenous infusion in adult patients with Wilson Disease. Pfizer is collaborating with Vivet on the clinical supply of VTX-801 for the Phase 1/2 clinical trial.

Gene Therapy 52

Gene Therapy Gene Clinical Trials Clinical Trials 52